ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

The typical treatment for estrogen receptor positive (ER+ ... t the same thing as a fully-fledged human being with all of the complex physiology and biochemistry that entails.